Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
22.12
USD
|
+1.14%
|
|
-0.94%
|
-27.71%
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,686
|
4,405
|
6,509
|
3,498
|
2,880
|
2,741
|
-
|
-
|
Enterprise Value (EV)
1 |
2,686
|
4,089
|
6,141
|
3,390
|
2,769
|
2,314
|
2,427
|
2,501
|
P/E ratio
|
40.8
x
|
-51.3
x
|
-45.9
x
|
-19.8
x
|
-14
x
|
-8.1
x
|
-8.64
x
|
-9.16
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
15.9
x
|
50.1
x
|
47.1
x
|
14.4
x
|
12
x
|
21.8
x
|
15.3
x
|
10.3
x
|
EV / Revenue
|
15.9
x
|
46.5
x
|
44.4
x
|
13.9
x
|
11.5
x
|
18.4
x
|
13.5
x
|
9.39
x
|
EV / EBITDA
|
-
|
-46.9
x
|
-43.6
x
|
-20.2
x
|
-14.4
x
|
-7.08
x
|
-6.49
x
|
-6.74
x
|
EV / FCF
|
16.7
x
|
-38.1
x
|
41.6
x
|
-17.9
x
|
-8.38
x
|
-4.88
x
|
-9.21
x
|
-9.57
x
|
FCF Yield
|
6%
|
-2.63%
|
2.4%
|
-5.57%
|
-11.9%
|
-20.5%
|
-10.9%
|
-10.5%
|
Price to Book
|
-
|
-
|
15.9
x
|
8.79
x
|
10.6
x
|
6.74
x
|
9.61
x
|
14.3
x
|
Nbr of stocks (in thousands)
|
95,301
|
102,292
|
104,259
|
105,849
|
107,193
|
123,897
|
-
|
-
|
Reference price
2 |
28.18
|
43.06
|
62.43
|
33.05
|
26.87
|
22.12
|
22.12
|
22.12
|
Announcement Date
|
11/25/19
|
11/23/20
|
11/22/21
|
11/28/22
|
11/29/23
|
-
|
-
|
-
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
168.8
|
87.99
|
138.3
|
243.2
|
240.7
|
125.7
|
179.4
|
266.4
|
EBITDA
1 |
-
|
-87.22
|
-140.8
|
-168.1
|
-192.5
|
-326.7
|
-374
|
-371.1
|
EBIT
1 |
61.19
|
-93.16
|
-149
|
-178.5
|
-205
|
-330.7
|
-331.6
|
-295.6
|
Operating Margin
|
36.25%
|
-105.87%
|
-107.77%
|
-73.39%
|
-85.16%
|
-263.08%
|
-184.88%
|
-110.98%
|
Earnings before Tax (EBT)
1 |
61.19
|
-84.55
|
-140.8
|
-172.7
|
-206.5
|
-340.9
|
-330
|
-317.1
|
Net income
1 |
67.97
|
-84.55
|
-140.8
|
-176.1
|
-205.3
|
-312.5
|
-303.7
|
-317.2
|
Net margin
|
40.27%
|
-96.09%
|
-101.85%
|
-72.39%
|
-85.27%
|
-248.62%
|
-169.32%
|
-119.09%
|
EPS
2 |
0.6900
|
-0.8400
|
-1.360
|
-1.670
|
-1.920
|
-2.730
|
-2.559
|
-2.415
|
Free Cash Flow
1 |
161
|
-107.3
|
147.7
|
-188.9
|
-330.6
|
-474.1
|
-263.7
|
-261.5
|
FCF margin
|
95.4%
|
-121.99%
|
106.78%
|
-77.67%
|
-137.34%
|
-377.17%
|
-147.01%
|
-98.18%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
236.9%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/25/19
|
11/23/20
|
11/22/21
|
11/28/22
|
11/29/23
|
-
|
-
|
-
|
Fiscal Period: September |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
38.28
|
27.44
|
151.8
|
32.41
|
31.58
|
62.55
|
146.3
|
15.82
|
16.1
|
3.551
|
55.71
|
27.26
|
35.14
|
25.53
|
26.33
|
EBITDA
1 |
-62.38
|
-60.75
|
44.15
|
-70.32
|
-81.17
|
-39.44
|
50.83
|
-99.43
|
-104.5
|
-132.3
|
-86.91
|
-81.15
|
-76.07
|
-115.9
|
-116.5
|
EBIT
1 |
-64.88
|
-63.32
|
41.55
|
-72.91
|
-83.83
|
-42.13
|
48.16
|
-102.7
|
-108.3
|
-136.5
|
-42.33
|
-77.41
|
-77.47
|
-90.35
|
-95.4
|
Operating Margin
|
-169.48%
|
-230.77%
|
27.37%
|
-224.94%
|
-265.49%
|
-67.36%
|
32.93%
|
-648.99%
|
-672.98%
|
-3,845.25%
|
-75.98%
|
-284%
|
-220.47%
|
-353.91%
|
-362.32%
|
Earnings before Tax (EBT)
1 |
-63.37
|
-62.87
|
44.37
|
-72.05
|
-82.16
|
-41.79
|
47.68
|
-103.4
|
-109
|
-138.7
|
-38.44
|
-81.72
|
-80.3
|
-114.7
|
-121.5
|
Net income
1 |
-63.37
|
-62.87
|
44.37
|
-72.05
|
-85.51
|
-41.81
|
47.68
|
-102.9
|
-109.7
|
-132.9
|
-15.55
|
-72.27
|
-69.2
|
-114.7
|
-121.5
|
Net margin
|
-165.54%
|
-229.13%
|
29.23%
|
-222.28%
|
-270.82%
|
-66.85%
|
32.6%
|
-650.53%
|
-681.36%
|
-3,741.59%
|
-27.92%
|
-265.14%
|
-196.92%
|
-449.18%
|
-461.55%
|
EPS
2 |
-0.6100
|
-0.6000
|
0.4100
|
-0.6800
|
-0.8100
|
-0.3900
|
0.4500
|
-0.9600
|
-1.020
|
-1.240
|
-0.2174
|
-0.6311
|
-0.5589
|
-0.8418
|
-0.8833
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/22/21
|
2/2/22
|
5/10/22
|
8/4/22
|
11/28/22
|
2/6/23
|
5/2/23
|
8/7/23
|
11/29/23
|
2/6/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
315
|
368
|
108
|
111
|
426
|
313
|
239
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
161
|
-107
|
148
|
-189
|
-331
|
-474
|
-264
|
-262
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-14.6%
|
-43.6%
|
-61.3%
|
-77.5%
|
-99.8%
|
-144%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
3.920
|
3.760
|
2.530
|
3.280
|
2.300
|
1.550
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-
|
-
|
-1.700
|
-
|
-
|
Capex
1 |
12
|
12
|
23.6
|
52.8
|
177
|
143
|
11.2
|
12
|
Capex / Sales
|
7.11%
|
13.58%
|
17.04%
|
21.7%
|
73.42%
|
113.66%
|
6.26%
|
4.52%
|
Announcement Date
|
11/25/19
|
11/23/20
|
11/22/21
|
11/28/22
|
11/29/23
|
-
|
-
|
-
|
Last Close Price
22.12
USD Average target price
53.66
USD Spread / Average Target +142.61% Consensus |
1st Jan change
|
Capi.
|
---|
| -27.71% | 2.74B | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|